Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

The nucleolar RNA methyltransferase Misu (NSun2) is required for mitotic spindle stability.

Hussain S, Benavente SB, Nascimento E, Dragoni I, Kurowski A, Gillich A, Humphreys P, Frye M.

J Cell Biol. 2009 Jul 13;186(1):27-40. doi: 10.1083/jcb.200810180.

2.

Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells.

Norde WJ, Overes IM, Maas F, Fredrix H, Vos JC, Kester MG, van der Voort R, Jedema I, Falkenburg JH, Schattenberg AV, de Witte TM, Dolstra H.

Blood. 2009 Mar 5;113(10):2312-23. doi: 10.1182/blood-2008-04-153825. Epub 2008 Dec 12.

3.

Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.

Spaapen R, Mutis T.

Best Pract Res Clin Haematol. 2008 Sep;21(3):543-57. doi: 10.1016/j.beha.2008.06.001. Review.

PMID:
18790454
4.

Understanding and harnessing the graft-versus-leukaemia effect.

Barrett AJ.

Br J Haematol. 2008 Sep;142(6):877-88. doi: 10.1111/j.1365-2141.2008.07260.x. Epub 2008 Jun 28. Review.

PMID:
18564358
5.

DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.

Rosinski KV, Fujii N, Mito JK, Koo KK, Xuereb SM, Sala-Torra O, Gibbs JS, Radich JP, Akatsuka Y, Van den Eynde BJ, Riddell SR, Warren EH.

Blood. 2008 May 1;111(9):4817-26. doi: 10.1182/blood-2007-06-096313. Epub 2008 Feb 25.

6.

Rituximab as salvage therapy for refractory chronic GVHD.

Mohty M, Marchetti N, El-Cheikh J, Faucher C, Fürst S, Blaise D.

Bone Marrow Transplant. 2008 May;41(10):909-11. doi: 10.1038/bmt.2008.12. Epub 2008 Feb 18. No abstract available.

PMID:
18278073
7.

Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays.

Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M.

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17494-9. Epub 2007 Oct 22.

8.

A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403.

Terakura S, Murata M, Warren EH, Sette A, Sidney J, Naoe T, Riddell SR.

Transplantation. 2007 May 15;83(9):1242-8.

PMID:
17496542
9.

NCBI GEO: mining tens of millions of expression profiles--database and tools update.

Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Edgar R.

Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5. Epub 2006 Nov 11.

10.

Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.

Pameijer CR, Navanjo A, Meechoovet B, Wagner JR, Aguilar B, Wright CL, Chang WC, Brown CE, Jensen MC.

Cancer Gene Ther. 2007 Jan;14(1):91-7. Epub 2006 Oct 6.

PMID:
17024231
11.

Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.

Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF.

Bone Marrow Transplant. 2006 Aug;38(3):203-9. Epub 2006 Jun 26.

PMID:
16799614
12.

Chronic graft-versus-host disease: Pathogenesis and clinical management.

Pérez-Simón JA, Sánchez-Abarca I, Díez-Campelo M, Caballero D, San Miguel J.

Drugs. 2006;66(8):1041-57. Review.

PMID:
16789791
13.

Minor histocompatibility antigens: from transplantation problems to therapy of cancer.

Goulmy E.

Hum Immunol. 2006 Jun;67(6):433-8. Epub 2006 Apr 6. Review.

PMID:
16728266
14.

Rituximab for steroid-refractory chronic graft-versus-host disease.

Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E.

Blood. 2006 Jul 15;108(2):756-62. Epub 2006 Mar 21.

15.

The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Brickner AG, Evans AM, Mito JK, Xuereb SM, Feng X, Nishida T, Fairfull L, Ferrell RE, Foon KA, Hunt DF, Shabanowitz J, Engelhard VH, Riddell SR, Warren EH.

Blood. 2006 May 1;107(9):3779-86. Epub 2006 Jan 3.

16.

Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling.

Mattoon D, Michaud G, Merkel J, Schweitzer B.

Expert Rev Proteomics. 2005 Dec;2(6):879-89. Review.

PMID:
16307517
17.
18.

Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.

Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, Handgretinger R, Barbin K, Jung G, Martin D, Niethammer D, Lang P.

Bone Marrow Transplant. 2005 Jul;36(2):91-7.

PMID:
15908973
19.

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.

Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J.

Blood. 2005 Apr 1;105(7):2973-8. Epub 2004 Dec 21.

20.

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation.

Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, Antin JH, Ritz J.

J Exp Med. 2004 Apr 19;199(8):1133-42.

Supplemental Content

Support Center